Actively Recruiting
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Led by Bristol-Myers Squibb · Updated on 2025-12-15
360
Participants Needed
6
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
CONDITIONS
Official Title
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Histologically or cytologically confirmed advanced, unresectable or metastatic solid tumor measurable by RECIST v1.1
- For colorectal cancer: locally advanced, metastatic, recurrent, or unresectable adenocarcinoma with disease progression after systemic cancer therapy including 5-FU, irinotecan, and/or oxaliplatin
- For non-small cell lung cancer: stage IIIB, IV, or recurrent disease confirmed histologically
- For NSCLC, prior treatment and progression on anti-PD-(L)1 therapy if available
- For gastric cancer: progressed or intolerant to at least one standard treatment in advanced or metastatic setting or progressed within 6 months of adjuvant therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You will not qualify if you...
- History of anaphylactic reactions to irinotecan and/or bevacizumab
- Prior therapy targeting CEACAM5
- Grade 3 or higher interstitial lung disease or pneumonitis
- Other protocol-defined inclusion or exclusion criteria as applicable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Actively Recruiting
2
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
3
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
4
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
5
Tasman Oncology Research
Southport, Queensland, Australia, 4215
Actively Recruiting
6
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain the NCT# and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here